Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03334591
Other study ID # HYF001
Secondary ID
Status Recruiting
Phase Phase 2
First received November 3, 2017
Last updated November 13, 2017
Start date October 1, 2017
Est. completion date December 1, 2019

Study information

Verified date October 2017
Source Anhui Provincial Hospital
Contact yifu He, doctor
Phone 0551-65327666
Email 834638033@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators hope that after this research, two different treatment methods' curative effects for advanced gastric cancer can be assessed. One is continuous use of apatinib, the other is 5 days' continuous use and 2 days' off of apatinib.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 1, 2019
Est. primary completion date October 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Male and female patients,age=18years

2. Confirmed by Pathology or histology of Gastric cancer

3. Patients who failed first-line chemotherapy

4. The ECOG physical status score:0 to 2

5. Expected survival =3months

6. Patients should be voluntary to the trail and provide with signed informed consent.

7. The researchers believe patients can benefit from the study.

Exclusion Criteria:

1. Pregnant or lactating women

2. Patients with a knowm history of allergic reactions and/ou hypersensitivity attributed to apatinib or its accessories

3. Patients with apatinib contraindications

4. Patients of doctors considered unsuitable for the trail

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Apatinib
Apatinib 500mg with Docetaxel 60mg/m2

Locations

Country Name City State
China Anhui Provincial Cancer Hospital Hefei Anhui

Sponsors (1)

Lead Sponsor Collaborator
Anhui Provincial Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary progress free survival(PFS) From data of randomization until the date of first dccumentde progression or date of death from any cause 1 year
Secondary disease control rate (DCR) investigators will assess treatment response according to Response Evaluation Criteria in Soid Tumor 1year
Secondary Objective tumor response rate(ORR) difined as the percentage of subjects having achieved confirmed Complete Response+Partial Response as best overall response according to radiological assessments 1year
Secondary overall survival (os) difined as the length of time from random assignment to death or to last contact 1year
Secondary Quality of life score a questionnaire developed to assess the quality of life of cancer patients 1 year
Secondary adverse events adverse events are evaluated according to National Cancer institute Common Terminology Criteria for Adverse Events 1 year